Data / Form D filings / NRX Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc.: Form D filings
NRX Pharmaceuticals, Inc., a biotechnology company in Wilmington, DE, filed 2 Form D notices with the SEC between 2017 and 2025. The latest, on March 7, 2025, reports $3.5 million sold of a $3.5 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1201 ORANGE STREET, SUITE 600, Wilmington, DE, 19801
- Phone
- (484) 254-6134
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1719406
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 7, 2025 | New notice | $3,500,000 | $3,500,000 | 2 | Jan 27, 2025 | sec.gov | |
| Nov 22, 2017 | New notice | $2,750,000 | $2,525,000 | $225,000 | 1 | Sep 26, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Patrick Flynn | Director | |
| Michael Abrams | Executive Officer | |
| Michael Taylor | Director | |
| Jonathan Javitt | Executive Officer, Director | |
| Chaim Hurvitz | Director | |
| Dennis McBride | Director |
Other biotechnology companies in Delaware that filed recently
- TCM Life Science Inc. $16,666 · Oct 26, 2026
- Amplica Bio, Inc. $30,000 · Sep 11, 2026
Every Form D from the week of Mar 3, 2025 · All recent filings in Delaware · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what NRX Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.